Last $0.19 USD
Change Today -0.0138 / -6.94%
Volume 191.3K
AVXL On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/14 - $0.60
52 Week Low
12/1/14 - $0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a pharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and various cancers. Its lead drug candidates include ANAVEX 2-73, which has completed Phase I single ascending dose clinical trial for the treatment of Alzheimer’s disease; and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept) for Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a drug candidate that is highly effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037 for the treatment of prostate cancer. The company was founded in 2006 and is based in New York, New York.

1 Employees
Last Reported Date: 08/6/14
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

anavex life sciences corp (AVXL) Key Developments

Anavex Announces Positive Phase 1 Data for ANAVEX 2-73

Anavex Life Sciences Corp. announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the company's investigational oral treatment for Alzheimer's, which has shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Observed adverse events included moderate and reversible headache and dizziness, which is common in drugs that target central nervous system (CNS) conditions, including Alzheimer's. No serious side effects were reported in this randomized, double-blind, placebo-controlled study, there was no study discontinuation due to adverse events, ANAVEX 2-73 was found to be safe and well tolerated, and the results indicate a favorable pharmacokinetics profile. Findings from the Phase 1 clinical trial were presented at CNS Summit 2014 in Boca Raton, Florida. A Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept(R)), is now underway. The Phase 1 clinical trial was a randomized, double-blind, placebo-controlled study in 22 healthy male volunteers. The participants received single, ascending oral doses of ANAVEX 2-73 ranging from 1 mg to 60 mg. The primary objective of the trial was to evaluate safety and tolerability together with pharmacokinetic parameters. Safety: No serious side effects were reported. There was no study discontinuation due to adverse events. No dose-limiting adverse events or lab abnormalities at doses of 1, 10, 30, 40 and 50mg were observed. Tolerability: Maximum tolerated dose (MTD) of ANAVEX 2-73 was defined as 55mg. Observed adverse events at doses above the MTD included dizziness and headache, which were moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including Alzheimer's disease. Across all doses, there were no differences in blood pressure and resting heart rate. Analysis of electrocardiograms (ECG) did not reveal any dose-related or time-dependent changes and the QT interval did not reveal any clinically significant changes. Additionally, no sign could be detected for any dose- or time-dependent changes for any of the hematology, biochemistry, and coagulation parameters. Pharmacokinetics (PK): ANAVEX 2-73 was determined to be suitable for daily oral dosing based on its PK profile. PK data revealed biotransformation of ANAVEX 2-73 to its main metabolite, which also actively targets sigma-1 and muscarinic receptors like its parent drug ANAVEX 2-73. Both maximum plasma concentration (Cmax), which relates to absorption and distribution of the drug in the blood, and area under the plasma concentration-time curve (AUC), which represents the total drug exposure over time, showed dose-proportional linear increases for both ANAVEX 2-73 and its metabolite. The biological half-life (T1/2) for ANAVEX 2-73 was 8.56 hours and 28.74 hours for its metabolite.

Anavex Life Sciences Corp. Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of Anavex 2-73 and Anavex Plus for Alzheimer's Disease

Anavex Life Sciences Corp. announced that it has received regulatory approval from the Ethics Committee in Australia to initiate a Phase 2a clinical trial of its proprietary compound, ANAVEX 2-73, as well as ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept(R)). The approved Phase 2a clinical trial is the first study of ANAVEX 2-73 in Alzheimer's patients. The investigational compound targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer's disease. Patient screening and enrollment will now commence. Results are expected in 2015. The Phase 2a study is designed as a randomized trial, with enrollment of 32 mild to moderate Alzheimer's disease patients at up to 7 sites. Its adaptive design stipulates that data be collected at a number of intervals, including at 3 and 6 months. This provides the opportunity for modification of one or more detailed aspects of the study based on analysis of data. It is believed this advantage will allow the trial to more efficiently demonstrate the effects of the drug. The trial will focus on the following key endpoints: bioavailability, dose finding and dose response, cognitive efficacy, and the relationship of ANAVEX 2-73 as a potential effective add-on therapy to donepezil, the current standard of care. ANAVEX 2-73 is an orally available small molecule being investigated for the treatment of Alzheimer's disease. In addition to preclinical data indicating that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer's disease, there was a highly encouraging synergistic effect observed between ANAVEX 2-73 and donepezil (Aricept(R)). The combined therapeutic, called ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually.

Anavex Life Sciences Corp. Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 11:30 AM

Anavex Life Sciences Corp. Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 11:30 AM. Venue: Convene Midtown East, New York, New York, United States. Speakers: Christopher U. Missling, Chairman, Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Secretary, Treasurer and Member of Scientific Advisory Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $0.19 USD -0.0138

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at